Longeveron Inc. (NASDAQ: LGVN) announced that its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE